Stasa Stankovic

Stasa Stankovic

Auto-generated profile, based on publicly available information

Stasa Stankovic

MRC Epidemiology Unit, Wellcome–MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
KKKatherine A. Kentistou
Katherine A. Kentistou
LKLena R. Kaisinger
Lena R. Kaisinger
SSStasa Stankovic
Stasa Stankovic
MVMarc Vaudel
Marc Vaudel
EOEdson Mendes de Oliveira
Edson Mendes de Oliveira
KOKen Ong
Ken Ong
Pubertal timing varies considerably and is associated with later health outcomes. We performed multi-ancestry genetic analyses on ~800,000 women, identifying 1,080 signals for age at menarche. Collectively, these explained 11% of trait variance in an independent sample. Women at the top and bottom 1% of polygenic risk exhibited ~11 and ~14-fold higher risks of delayed and precocious puberty, respectively. We identified several genes harboring rare loss-of-function variants in ~200,000 women, including variants in ZNF483, which abolished the impact of polygenic risk. Variant-to-gene mapping approaches and mouse gonadotropin-releasing hormone neuron RNA sequencing implicated 665 genes, including an uncharacterized G-protein-coupled receptor, GPR83, which amplified the signaling of MC3R, a key nutritional sensor. Shared signals with menopause timing at genes involved in DNA damage response suggest that the ovarian reserve might signal centrally to trigger puberty. We also highlight body size-dependent and independent mechanisms that potentially link reproductive timing to later life disease.

11 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
SSStasa Stankovic
Stasa Stankovic
SSSaleh Shekari
Saleh Shekari
QHQin Qin Huang
Qin Qin Huang
EGEugene J. Gardner
Eugene J. Gardner
EIErna V. Ivarsdottir
Erna V. Ivarsdottir
AMAnna Murray
Anna Murray
Human genetic studies of common variants have provided substantial insight into the biological mechanisms that govern ovarian ageing1. Here we report analyses of rare protein-coding variants in 106,973 women from the UK Biobank study, implicating genes with effects around five times larger than previously found for common variants (ETAA1, ZNF518A, PNPLA8, PALB2 and SAMHD1). The SAMHD1 association reinforces the link between ovarian ageing and cancer susceptibility1, with damaging germline variants being associated with extended reproductive lifespan and increased all-cause cancer risk in both men and women. Protein-truncating variants in ZNF518A are associated with shorter reproductive lifespan—that is, earlier age at menopause (by 5.61 years) and later age at menarche (by 0.56 years). Finally, using 8,089 sequenced trios from the 100,000 Genomes Project (100kGP), we observe that common genetic variants associated with earlier ovarian ageing associate with an increased rate of maternally derived de novo mutations. Although we were unable to replicate the finding in independent samples from the deCODE study, it is consistent with the expected role of DNA damage response genes in maintaining the genetic integrity of germ cells. This study provides evidence of genetic links between age of menopause and cancer risk.

2 March 2023 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
IMIain Mathieson
Iain Mathieson
FDFelix R. Day
Felix R. Day
NBNicola Barban
Nicola Barban
FTFelix C. Tropf
Felix C. Tropf
DBDavid M. Brazel
David M. Brazel
JPJohn R. B. Perry
John R. B. Perry

22 June 2023 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
SSSaleh Shekari
Saleh Shekari
SSStasa Stankovic
Stasa Stankovic
EGEugene J. Gardner
Eugene J. Gardner
GHGareth Hawkes
Gareth Hawkes
KKKatherine A. Kentistou
Katherine A. Kentistou
AMAnna Murray
Anna Murray

7 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYajie Zhao
Yajie Zhao
SSStasa Stankovic
Stasa Stankovic
MKMine Koprulu
Mine Koprulu
EWEleanor Wheeler
Eleanor Wheeler
FDFelix R. Day
Felix R. Day
JPJohn R. B. Perry
John R. B. Perry
Mosaic loss of chromosome Y (LOY) in leukocytes is the most common form of clonal mosaicism, caused by dysregulation in cell-cycle and DNA damage response pathways. Previous genetic studies have focussed on identifying common variants associated with LOY, which we now extend to rarer, protein-coding variation using exome sequences from 82,277 male UK Biobank participants. We find that loss of function of two genes—CHEK2 and GIGYF1—reach exome-wide significance. Rare alleles in GIGYF1 have not previously been implicated in any complex trait, but here loss-of-function carriers exhibit six-fold higher susceptibility to LOY (OR = 5.99 [3.04–11.81], p = 1.3 × 10−10). These same alleles are also associated with adverse metabolic health, including higher susceptibility to Type 2 Diabetes (OR = 6.10 [3.51–10.61], p = 1.8 × 10−12), 4 kg higher fat mass (p = 1.3 × 10−4), 2.32 nmol/L lower serum IGF1 levels (p = 1.5 × 10−4) and 4.5 kg lower handgrip strength (p = 4.7 × 10−7) consistent with proposed GIGYF1 enhancement of insulin and IGF-1 receptor signalling. These associations are mirrored by a common variant nearby associated with the expression of GIGYF1. Our observations highlight a potential direct connection between clonal mosaicism and metabolic health.

27 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
EGEugene J. Gardner
Eugene J. Gardner
KKKatherine A. Kentistou
Katherine A. Kentistou
SSStasa Stankovic
Stasa Stankovic
SLSamuel Lockhart
Samuel Lockhart
EWEleanor Wheeler
Eleanor Wheeler
JPJohn R. B. Perry
John R. B. Perry
Type 2 diabetes (T2D) is a chronic metabolic disorder with a significant genetic component. While large-scale population studies have identified hundreds of common genetic variants associated with T2D susceptibility, the role of rare (minor allele frequency < 0.1%) protein coding variation is less clear. To this end, we performed a gene burden analysis of 18,691 genes in 418,436 (n=32,374 T2D cases) individuals sequenced by the UK Biobank (UKBB) study to assess the impact of rare genetic variants on T2D risk. Our analysis identified T2D associations at exome-wide significance (P < 6.9×10 -7 ) with rare, damaging variants within previously identified genes including GCK, GIGYF1, HNF1A , and TNRC6B . In addition, individuals with rare, damaging missense variants in the genes ZEB2 (N=31 carriers; OR=5.5 [95% CI=2.5-12.0]; p=6.4×10 -7 ), MLXIPL (N=245; OR=2.3 [1.6-3.2]; p=3.2×10 -7 ), and IGF1R (N=394; OR=2.4 [1.8-3.2]; p=1.3×10 -10 ) have higher risk of T2D. Carriers of damaging missense variants within IGF1R were also shorter (-2.2cm [-1.8-2.7]; p=1.2×10 -19 ) and had higher circulating protein levels of insulin-like growth factor-1 (IGF-1; 2.3 nmol/L [1.7-2.9] p=2.8×10 -14 ), indicating relative IGF-1 resistance. A likely causal role of IGF-1 resistance on T2D was further supported by Mendelian randomisation analyses using common variants. Our results increase our understanding of the genetic architecture of T2D and highlight a potential therapeutic benefit of targeting the Growth Hormone/IGF-1 axis.